Statin analogs for periodontitis

Bone-targeting statin analogs for periodontal bone regeneration

  • Novel treatment approach for periodontal disease
  • Potent bone binding statin analogs
  • Effectively prevent bone loss associated with periodontal disease

 
Licensing Manager: Steve Schreiner, Ph.D.
sjschreiner@unmc.edu or 402-559-2176
 

Description

Bone-targeting statin analogs for periodontal bone regeneration

Dong Wang, Ph.D.

Dong Wang, Ph.D.

University of Nebraska Medical Center scientists have developed a better therapy to prevent bone loss in periodontal disease.
 
Periodontitis is a common infection of the gums that damages tissue, destroys bone and is the most common cause of tooth loss in adults.
 
If left untreated, bacteria responsible for periodontitis can enter the bloodstream and cause more serious health problems like coronary artery disease and stroke.
 
While periodontitis can be treated, rebuilding the damaged bone has been a challenging task and current treatments have had limited success.
 
Recent studies have shown that cholesterol-lowering statins can help prevent bone loss and improve bone density. Statins may be a useful therapy for patients suffering from periodontal disease, which afflicts about half of all Americans.
 
Dong Wang, Ph.D. and his team have created more effective statins specific for the treatment of periodontitis. Their water-soluble, bone-targeting statin analogs can be applied directly to the periodontal region during routine treatment procedures.
 
In animal studies, the statin analogs had a stronger binding affinity to the tooth surface and were more efficient at preventing bone loss compared to regular statins.
 
These statin analogs provide a more effective therapeutic option for the treatment and prevention of bone loss associated with periodontal disease.
 
To discuss licensing opportunities please contact Steve Schreiner, Ph.D., at sjschreiner@unmc.edu or 402-559-2176.